Agricultural Inputs Maker - Proprietary Crop Nutrient Formulations

$8.8M

Revenue

$2.2M

SDE

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a 50-year-old agricultural inputs manufacturer that develops and sells proprietary nutrient and micronutrient solutions, including biostimulants, designed to improve crop yields and nutrient efficiency. Products are applied at critical growth stages from planting through maturity, serving growers across row crop and specialty crop applications. The business runs an integrated in-house platform spanning formulation, manufacturing, packaging, and distribution out of company-owned facilities, which gives it quality control and fulfillment flexibility that most input resellers cannot match.

The company does $8.77M in revenue at a $2.21M EBITDA, a 28.6% margin that has held steady from 2022 through 2025. That kind of consistency is rare in ag and signals genuine pricing power tied to differentiated formulations rather than commodity blending. Revenue is supported by a repeat grower base, long-tenured sales consultants, direct relationships, and an established early-order program that creates seasonal demand visibility.

This is a boring, durable cash machine. Farmers buy inputs every season regardless of the macro cycle, and the proprietary IP plus five decades of field testing create switching costs that protect the margin. The growth story is straightforward geographic expansion across the Midwest, Great Plains, and select international markets, plus deeper product line extensions and channel buildout.

Why we like it

Earnings quality is strong and stable. A 28.6% adjusted EBITDA margin held flat across four years (2022 to 2025) on $8.77M revenue, producing $2.21M EBITDA. Steady margins in a notoriously cyclical commodity-adjacent space signal real pricing power from proprietary formulations rather than commodity pass-through.
The moat is genuine and hard to replicate. Fifty years of testing, refinement, and commercial application built proprietary biostimulant and nutrient-efficiency formulations that a new entrant cannot simply reverse-engineer. Combined with in-house formulation, manufacturing, packaging, and distribution, the company controls quality and supply end to end.
Demand is recession-resistant and recurring. Growers buy crop inputs every season regardless of the economy because they directly affect yield and revenue. The repeat customer base, direct grower relationships, and an established early-order program create predictable seasonal demand and revenue visibility most manufacturers would envy.
There is a clear operator playbook for growth. The listing maps out geographic expansion across the Midwest, Great Plains, and international markets, plus new formulation combinations and expanded sales consultant and distributor recruitment. These are executable levers, not blue-sky speculation, and align with rising demand for efficiency-driven and sustainable farming.

How to improve it

Push hard on the early-order program. Incentivize growers to commit volume before the season with pricing tiers and financing options. This locks in revenue, improves production planning, and reduces working capital strain on raw materials, directly strengthening retention and forecasting.
Expand the sales consultant network into adjacent regions. The listing flags the Midwest and Great Plains as underpenetrated. Recruiting and training agronomy-savvy consultants who own grower relationships is the proven channel here, and each productive rep should pay for itself within a season or two.
Extend the product portfolio with new proprietary formulation combinations. Target both row crop and specialty crop applications to broaden the addressable acreage. With in-house formulation capability, line extensions carry low incremental cost and leverage the existing 50-year R&D base.
Pursue distributor and strategic partnerships. Aligning with larger agricultural input and biological product platforms can multiply reach without building owned infrastructure. A co-marketing or private-label arrangement with a major ag retailer could open national shelf space quickly.
Build out international markets methodically. Start with regions that have similar crop profiles and regulatory pathways for biostimulants. International expansion can de-risk the geographic concentration of the current footprint and add a second growth engine.
Systematize the agronomic data into a customer-facing asset. Capture grower yield results from product trials and turn them into ROI case studies. Quantified yield-per-dollar proof points shorten sales cycles, justify premium pricing, and reduce reliance on individual rep relationships.
Tighten manufacturing capacity utilization and procurement. Audit raw material sourcing for volume discounts and lock in supply contracts ahead of season. Margin is already strong, and incremental procurement and throughput gains drop straight to EBITDA.

Diligence notes

Verify the proprietary IP position. Confirm whether the formulations are protected by patents, trade secrets, or registered trademarks, and what happens to that protection post-sale. The entire moat and margin depend on these formulations not being easily copied, so understand exactly what is owned versus reliant on undocumented know-how.
Assess customer and consultant concentration. The repeat base is a strength, but find out the revenue share of the top 10 growers and distributors, and how dependent sales are on a handful of long-tenured consultants. Quantify the risk if a key rep retires or walks with their book.
Confirm regulatory compliance and product registrations. Ag inputs, especially biostimulants and nutrient products, face state-by-state and federal labeling and registration requirements. Verify all products are properly registered in every market sold and that there are no pending regulatory issues that could halt sales.
Stress-test the EBITDA adjustments. The 28.6% margin is described as adjusted, so scrutinize every add-back and confirm a clean trailing EBITDA. Also examine working capital seasonality given the early-order program and inventory build, since the headline EBITDA may overstate distributable free cash flow.
Understand the real estate and asking price structure. Real estate is owned and the price was not disclosed. Clarify whether the company-owned facilities are included in the sale or sold or leased separately, since that materially changes the effective operating multiple and your capital outlay.
Probe the seller's reason for selling and transition plan. With a 50-year history, founder or family ownership and undocumented agronomic expertise are likely. Confirm how product knowledge, supplier relationships, and grower goodwill transfer, and negotiate a meaningful transition period or earnout.

Source

Originally listed on BizBuySell. View original listing →